Peptide Mimetic

A peptidomimetic is a molecule designed to reproduce the three-dimensional structure and biological function of a native peptide while displaying improved pharmacokinetic properties: increased proteolysis resistance, oral bioavailability, extended plasma half-life, enhanced membrane permeability. The concept is a major bridge between peptide chemistry and medicinal chemistry, and a central strategy to transform a promising peptide into a viable drug candidate.

Several structural approaches exist to design peptidomimetics. (1) Non-natural amino acid substitution: D-isomers, β-amino acids, modified side-chain amino acids, Aib residues (α-aminoisobutyric acid). (2) Peptide bond modifications: reversed amide bonds (retro-inverso), amide nitrogen methylation (N-methylation), bioisosteres (thioamides, triazoles, alkenes). (3) Cyclization: head-to-tail, side-to-side, grafting on rigid scaffold (cyclotides, stapled peptides). (4) Backbone replacement: peptoids (side chain on N rather than Cα), β-peptides, peptide nucleic acids (PNA).

Peptidomimetics have enabled development of many approved drugs: renin inhibitors (aliskiren), HIV protease inhibitors (saquinavir, ritonavir), GPCR antagonists (aprepitant for substance P NK1 receptor), thrombin inhibitors (dabigatran), oral GLP-1 agonists (oral semaglutide in SNAC formulation). Aileron Therapeutics' stapled peptide technology explores peptidomimetics targeting historically undruggable intracellular protein-protein interactions.

In RUO peptide research, peptidomimetic design remains mainly within academic and industrial scope. RUO catalogs mainly offer native peptides or their classical stabilized analogs (amidation, acetylation, punctual substitutions). Complex peptidomimetics are rather dedicated-order products (custom synthesis). Understanding peptidomimetic concepts is nonetheless essential to interpret scientific literature and design rigorous pharmacological experiments.

Peptide mimetics are classified by their degree of divergence from the parent peptide: Class I — modified peptides keeping the native main chain but with substitutions (D-amino acids, Aib, N-methylation, modified amide bond CH2-NH or CH2-S); Class II — topography mimetics preserving side-chain presentation but on non-peptide backbone (beta-peptides, peptoids with chains on nitrogen vs carbon α); Class III — pharmacophore mimetics, non-peptide small molecules reproducing key pharmacophoric interaction (e.g., MK-677 ibutamoren mimicking ghrelin on GHS-R1a).

Peptide mimetism strategies aim to solve pharmacological limitations of native peptides: low oral bioavailability, short half-life, production cost, potential immunogenicity. Orally active peptidomimetics that reached clinical research include: MK-677 / ibutamoren (oral ghrelin), cilengitide (αvβ3/αvβ5 integrins), romidepsin (HDAC), eribulin (tubulin). In preclinical research, Dihexa is a remarkable N-hexanoyl-Tyr-Ile-hexanoic-amide peptidomimetic derived from angiotensin IV for study of HGF/c-Met pathways in cognition (Harding WSU 2010-2012). Rational design relies on crystallographic data (cryo-EM, X-ray) or AlphaFold 3 / RFdiffusion predictions.